Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial

Phase I ◽

Phase I Clinical Trial ◽

Bcg Vaccine ◽

Double Blind ◽

Double Blind Placebo ◽

Syncytial Virus ◽

Recombinant Bcg

Angiotensin Receptor Neprilysin Inhibitor

A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2021.1985464 ◽

2021 ◽

Author(s):

Yue Hu ◽

Hong Zhang ◽

Xiaojiao Li ◽

Jiajia Mai ◽

Lizhi Yang ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Dose Escalation ◽

Multiple Dose ◽

Phase I Clinical Trial ◽

Angiotensin Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Neprilysin Inhibitor ◽

Phase I/II, Double-blind, Placebo-controlled, Multi-dose Escalation Trial of a Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody (MEDI-493) in Children Hospitalized with RSV • 906

Pediatric Research ◽

10.1203/00006450-199804001-00927 ◽

1998 ◽

Vol 43 ◽

pp. 156-156 ◽

Cited By ~ 5

Author(s):

Xavier Saez-Llorens ◽

Maria T Moreno ◽

Octavio Ramilo ◽

Pablo J Sanchez ◽

Edward M Connor

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Dose Escalation ◽

Double Blind ◽

Double Blind Placebo ◽

The safety and tolerability of alkaloids from Alstonia scholaris leaves in healthy Chinese volunteers: a single-centre, randomized, double-blind, placebo-controlled phase I clinical trial

Pharmaceutical Biology ◽

10.1080/13880209.2021.1893349 ◽

2021 ◽

Vol 59 (1) ◽

pp. 484-493

Author(s):

Zhong-Ping Gou ◽

Yun-Li Zhao ◽

Lin-Ling Zou ◽

Ying Wang ◽

Shi-Qing Shu ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Phase I Clinical Trial ◽

Single Centre ◽

Double Blind ◽

Double Blind Placebo ◽

Alstonia Scholaris ◽

Healthy Chinese

Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/rccm.201810-1921oc ◽

2019 ◽

Vol 200 (4) ◽

pp. 481-492 ◽

Cited By ~ 7

Author(s):

Stephanie Ascough ◽

Iris Vlachantoni ◽

Mohini Kalyan ◽

Bert-Jan Haijema ◽

Sanna Wallin-Weber ◽

...

Keyword(s):

Clinical Trial ◽

Controlled Clinical Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Systemic Immunity ◽

Intranasal Vaccine ◽

Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trial

Vaccine ◽

10.1016/j.vaccine.2012.03.010 ◽

2012 ◽

Vol 30 (22) ◽

pp. 3295-3303 ◽

Cited By ~ 71

Author(s):

Yan-Ping Li ◽

Zheng-Lun Liang ◽

Qiang Gao ◽

Li-Rong Huang ◽

Qun-Ying Mao ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Enterovirus 71 ◽

Phase I Clinical Trial ◽

Human Enterovirus ◽

Double Blind ◽

Human Enterovirus 71

A randomized, double-blind, phase I clinical trial of fetal cell-based skin substitutes on healing of donor sites in burn patients

Burns ◽

10.1016/j.burns.2018.10.016 ◽

2019 ◽

Vol 45 (4) ◽

pp. 914-922 ◽

Cited By ~ 9

Author(s):

Mahnoush Momeni ◽

Nasrin Fallah ◽

Amir Bajouri ◽

Tooran Bagheri ◽

Zahra Orouji ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Phase I Clinical Trial ◽

Burn Patients ◽

Fetal Cell ◽

Skin Substitutes ◽

Double Blind

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-ESCALATION TRIAL OF A HUMANIZED RESPIRATORY SYNCYTIAL VIRUS (RSV) MONOCLONAL ANTIBODY (MEDI-493) IN HIGH RISK INFANTS. • 768

Pediatric Research ◽

10.1203/00006450-199704001-00788 ◽

1997 ◽

Vol 41 ◽

pp. 130-130

Author(s):

K. N. Siva Subramanian ◽

L. Weisman ◽

T. Rhodes ◽

E. Connor

Keyword(s):

Monoclonal Antibody ◽

High Risk ◽

Dose Escalation ◽

Double Blind ◽

Double Blind Placebo ◽

Syncytial Virus ◽

High Risk Infants

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.0912186107 ◽

2010 ◽

Vol 107 (19) ◽

pp. 8800-8805 ◽

Cited By ~ 278

Author(s):

J. DeVincenzo ◽

R. Lambkin-Williams ◽

T. Wilkinson ◽

J. Cehelsky ◽

S. Nochur ◽

...

Keyword(s):

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

P449 Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjy222.573 ◽

2019 ◽

Vol 13 (Supplement_1) ◽

pp. S336-S336 ◽

Cited By ~ 2

Author(s):

J Ellis ◽

D Marks ◽

C Barrett ◽

T Hopkins ◽

A Richards ◽

...

Keyword(s):

Clinical Trial ◽

T Cell ◽

Phase I ◽

Double Blind ◽

Double Blind Placebo ◽

Selective Depletion

The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial

Yearbook of Pediatrics ◽

10.1016/s0084-3954(09)79553-3 ◽

2011 ◽

Vol 2011 ◽

pp. 504-506

Author(s):

J.A. Stockman

Keyword(s):

Virus Infection ◽

Respiratory Syncytial Virus Infection ◽

Inhaled Corticosteroids ◽

Controlled Trial ◽

High Dose ◽

Double Blind ◽

Double Blind Placebo ◽